(Q34044333)

30 July 2017

1 reference

title

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

AASLD/IDSA HCV Guidance Panel

series ordinal

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

25 June 2015

1 reference

30 July 2017

1 reference

30 July 2017

volume

62

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

932-954

1 reference

Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization

30 July 2017

cites work

1 reference

7 January 2021

Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

1 reference

7 January 2021

Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008

1 reference

7 January 2021

Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010.

1 reference

7 January 2021

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid

1 reference

7 January 2021

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

1 reference

7 January 2021

Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

1 reference

7 January 2021

Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic

1 reference

7 January 2021

Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011.

1 reference

7 January 2021

HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection.

1 reference

7 January 2021

Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006

1 reference

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

7 January 2021

The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse

1 reference

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

7 January 2021

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

1 reference

7 January 2021

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

1 reference

7 January 2021

Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion.

1 reference

7 January 2021

Alcohol and hepatitis C

1 reference

7 January 2021

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

1 reference

7 January 2021

Characteristics of patients with dual infection by hepatitis B and C viruses

1 reference

7 January 2021

Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Contribution of obesity to hepatitis C-related fibrosis progression

1 reference

7 January 2021

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

7 January 2021

Hepatitis C in the United States

1 reference

7 January 2021

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

1 reference

7 January 2021

Lack of access to treatment as a barrier to HCV screening: a facility-based assessment in the Indian health service

1 reference

7 January 2021

A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care

1 reference

7 January 2021

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

1 reference

7 January 2021

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

1 reference

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

1 reference

7 January 2021

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

1 reference

7 January 2021

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

7 January 2021

Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies

1 reference

7 January 2021

Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.

1 reference

7 January 2021

Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.

1 reference

7 January 2021

Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

1 reference

7 January 2021

Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection

1 reference

7 January 2021

Regression of splenic lymphoma after treatment of hepatitis C virus infection

1 reference

7 January 2021

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

1 reference

7 January 2021

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

1 reference

7 January 2021

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

1 reference

7 January 2021

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

1 reference

7 January 2021

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

1 reference

7 January 2021

Management of hepatocellular carcinoma: An update

1 reference

7 January 2021

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection

1 reference

7 January 2021

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

1 reference

7 January 2021

Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

1 reference

7 January 2021

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

7 January 2021

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

7 January 2021

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

1 reference

7 January 2021

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

1 reference

7 January 2021

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

1 reference

7 January 2021

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

7 January 2021

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

7 January 2021

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

7 January 2021

Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry

1 reference

7 January 2021

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

7 January 2021

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

1 reference

7 January 2021

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

1 reference

7 January 2021

Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

1 reference

7 January 2021

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

1 reference

7 January 2021

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

1 reference

7 January 2021

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

1 reference

7 January 2021

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

1 reference

7 January 2021

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

1 reference

7 January 2021

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

7 January 2021

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

1 reference

7 January 2021

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study

1 reference

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

7 January 2021

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

7 January 2021

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

7 January 2021

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

1 reference

7 January 2021

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

1 reference

7 January 2021

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

1 reference

7 January 2021

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

1 reference

7 January 2021

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection

1 reference

7 January 2021

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

1 reference

7 January 2021

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion

1 reference

7 January 2021

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

1 reference

7 January 2021

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.27950

1 reference

30 July 2017

1 reference